Mad Money

Cramer Slaps a ‘Buy’ on Biogen

Cramer: Biogen Idec's Profit Pipeline

All this week, Cramer has been highlighting drug companies that could have a breakout year and on Thursday, he looked at Biogen.

The biotechnology firm not only has a number of popular products on the market, the “Mad Money” host noted, it has an excellent pipeline of drugs in development, too.  It’s main focus is on treating multiple sclerosis, which is a chronic disease that attacks the central nervous system. There is no cure, but there are a bunch of drugs that aim to prevent relapses and keep the disease in remission.

Biogen currently has two MS treatments on the market, accounting for 60 percent of its total business. More importantly, though, it’s developing a new orally-delivered therapy that could be the most effective treatment yet. Cramer thinks it could make Biogen a fortune. It’s called BG-12 and given it receives FDA approval, it could go to market by the end of the year. The drug could help Biogen rake in $1.5 billion in sales in 2015, which would be impressive given its total revenues in 2011 was $5 billion.

The stock is currently near its highs, but Cramer still thinks it’s a buy because the future looks bright for this biotech company.

Call Cramer: 1-800-743-CNBC

Questions for Cramer?

Questions, comments, suggestions for the Mad Money website?

Related Tags